Dispatch Biotherapeutics
PrivateLast Round
Series A
Jul 23, 2025
Total Funding Raised
$216M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Dispatch Biotherapeutics is a biotechnology company that develops immunotherapy-based cancer treatment technologies designed to expand curative potential across solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dispatch Biotherapeutics Comparables
Compare Dispatch Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CREATE Medicines | 81% | |
| Eureka Therapeutics | 77% | |
| ArsenalBio | 76% |
Dispatch Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 23, 2025 |
Key People
Founding team and executive leadership
Dispatch Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| University of Pennsylvania Office of Investments | Series A |
| Stanford University | Series A |
| ARCH Venture Partners | Seed, Series A |
| Parker Institute for Cancer Immunotherapy | Seed, Series A |
| ARCH Venture Partners | Series A |
| Alexandria Venture Investments | Series A |
| Alexandria Venture Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 162% MoM, reaching 3.8K.
- Mar 1, 2026
Collaboration with University of Pennsylvania and other leading institutions.
Dispatch Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Dispatch Biotherapeutics's valuation, stock price, and market status.
Is Dispatch Biotherapeutics a public or private company?
Dispatch Biotherapeutics is a private company.
What is the current stock price of Dispatch Biotherapeutics?
Dispatch Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Dispatch Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Dispatch Biotherapeutics worth (valuation)?
Valuation information for Dispatch Biotherapeutics is not publicly available.
Can I buy Dispatch Biotherapeutics stock?
Dispatch Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Dispatch Biotherapeutics's last funding round?
Dispatch Biotherapeutics's most recent funding round was Series A on July 23, 2025.
Who are the main investors in Dispatch Biotherapeutics?
Key investors in Dispatch Biotherapeutics include ARCH Venture Partners, Parker Institute for Cancer Immunotherapy, ARCH Venture Partners.
Will Dispatch Biotherapeutics IPO soon?
No public IPO plans have been announced for Dispatch Biotherapeutics.
How can I track Dispatch Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Dispatch Biotherapeutics's shares on secondary markets.